Merus NV (FRA:2GH)
€ 48.4 -0.4 (-0.82%) Market Cap: 3.34 Bil Enterprise Value: 3.04 Bil PE Ratio: 0 PB Ratio: 8.88 GF Score: 61/100

Merus NV Investor Call Transcript

Apr 17, 2023 / 10:30PM GMT
Release Date Price: €19 (+9.20%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Merus investor call. I would now like to turn the call over to Kathleen Farren, Investor Relations, Corporate Communications. Please go ahead.

Kathleen Farren
Merus NV - IR

Good evening from Orlando. Thank you for joining our call today. Tonight, we will be discussing the data presented in the Oral Plenary session of this year's American Association for Cancer Research or AACR annual meeting. The slide presentation is available on our website at www.merus.nl.

On this call, we will also make certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These may include statements about our future expectations and plans and events and circumstances, including about finances, intellectual property, projections about Merus's clinical development for 2023 and beyond, and timing for plans and for meeting clinical and regulatory anticipated milestones related to petosemtamab and our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot